Abstract
Erectile dysfunction is a condition that is estimated to affect more than 30 million men in the United States alone. The prevalence of erectile dysfunction is increased with age and is often secondary to diseases such as depression, hypertension and diabetes. Causes of erectile dysfunction include physical injury to the cavernosum and abnormal cerebral and peripheral nervous system functioning. However, many cases of erectile dysfunction are the result of dysfunctional signaling in the cavernosal vasculature. This article will detail the important role of a vasoconstrictor mechanism mediated by the small G-protein RhoA and a downstream serine/threonine kinase, Rho-kinase, in the maintenance of penile flaccidity. Recent evidence demonstrates that inhibition of endogenous Rho-kinase initiates an erectile response in an in vivo rat model. These initial findings introduce a novel potential therapeutic approach for the treatment of erectile dysfunction.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 601-606 |
| Number of pages | 6 |
| Journal | Drug News and Perspectives |
| Volume | 14 |
| Issue number | 10 |
| State | Published - Dec 1 2001 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery
Cite this
Rho-kinase as a potential target for the treatment of erectile dysfunction. / Chitaley, Kanchan; Webb, R. Clinton; Mills, Thomas M.
In: Drug News and Perspectives, Vol. 14, No. 10, 01.12.2001, p. 601-606.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Rho-kinase as a potential target for the treatment of erectile dysfunction
AU - Chitaley, Kanchan
AU - Webb, R. Clinton
AU - Mills, Thomas M.
PY - 2001/12/1
Y1 - 2001/12/1
N2 - Erectile dysfunction is a condition that is estimated to affect more than 30 million men in the United States alone. The prevalence of erectile dysfunction is increased with age and is often secondary to diseases such as depression, hypertension and diabetes. Causes of erectile dysfunction include physical injury to the cavernosum and abnormal cerebral and peripheral nervous system functioning. However, many cases of erectile dysfunction are the result of dysfunctional signaling in the cavernosal vasculature. This article will detail the important role of a vasoconstrictor mechanism mediated by the small G-protein RhoA and a downstream serine/threonine kinase, Rho-kinase, in the maintenance of penile flaccidity. Recent evidence demonstrates that inhibition of endogenous Rho-kinase initiates an erectile response in an in vivo rat model. These initial findings introduce a novel potential therapeutic approach for the treatment of erectile dysfunction.
AB - Erectile dysfunction is a condition that is estimated to affect more than 30 million men in the United States alone. The prevalence of erectile dysfunction is increased with age and is often secondary to diseases such as depression, hypertension and diabetes. Causes of erectile dysfunction include physical injury to the cavernosum and abnormal cerebral and peripheral nervous system functioning. However, many cases of erectile dysfunction are the result of dysfunctional signaling in the cavernosal vasculature. This article will detail the important role of a vasoconstrictor mechanism mediated by the small G-protein RhoA and a downstream serine/threonine kinase, Rho-kinase, in the maintenance of penile flaccidity. Recent evidence demonstrates that inhibition of endogenous Rho-kinase initiates an erectile response in an in vivo rat model. These initial findings introduce a novel potential therapeutic approach for the treatment of erectile dysfunction.
UR - http://www.scopus.com/inward/record.url?scp=0035724390&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035724390&partnerID=8YFLogxK
M3 - Article
C2 - 12806426
AN - SCOPUS:0035724390
VL - 14
SP - 601
EP - 606
JO - Drug News and Perspectives
JF - Drug News and Perspectives
SN - 0214-0934
IS - 10
ER -